No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
349 |
4. Check minimum number of eventsNone |
349 |
5. Include endpointsNone |
349 |
6. Filter based on genotype QC (FinnGen only) |
335 |
Control definitions (FinnGen only)
- Control exclude
- H7_VISUALDISTBLIND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H54
- Name in latin
- Amblyopia unius oculi
Similar endpoints
↥List of similar endpoints to
Severe visual impairment, monocular
based on the number of shared cases.
Similar with more cases:
- Visual impairment including blindness (binocular or monocular)
- Visual disturbances and blindness
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2596 | 1398 | 1186 |
| Only index persons | 2197 | 1205 | 992 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.03 |
| Only index persons | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 50.93 | 57.12 | 43.50 |
| Only index persons | 56.01 | 61.87 | 48.88 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 335 | 206 | 129 |
| Unadjusted period prevalence (%) | 0.07 | 0.07 | 0.06 |
| Median age at first event (years) | 66.59 | 65.33 | 68.60 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 349
- Matched controls
- 3490
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H54.5
ICD-10 Finland
Severe visual impairment, monocular
4503599627370496.0
307.7
345
6
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
11.7
70.4
81
88
H53.1
ICD-10 Finland
Subjective visual disturbances
18.0
51.2
43
27
XCW99
NOMESCO Finland
Other investigative procedure of eye
6.2
46.0
95
198
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
6.0
42.0
89
189
XCK00
NOMESCO Finland
Perimetry
6.8
36.5
64
112
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
200.0
35.5
36
*
CKD05
NOMESCO Finland
Puncture of vitreous body with injection of medication
7.2
35.0
57
92
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.3
34.7
119
372
Z96.1
ICD-10 Finland
Presence of intraocular lens
4.2
32.8
118
380
S01ED51
ATC
timolol, combinations; ophthalmic
5.1
29.6
72
170
H53.0
ICD-10 Finland
Amblyopia ex anopsia
140.0
25.0
26
*
H35.31
ICD-10 Finland
Senile macular degeneration (atrophic)(exudative)
6.1
23.9
44
80
H35.30
ICD-10 Finland
Kuhnt-Junius degeneration
5.3
23.8
53
115
S01EA05
ATC
brimonidine; ophthalmic
8.2
23.8
33
44
XCK10
NOMESCO Finland
Photography of fundus of eye
4.2
22.7
70
197
H34.8
ICD-10 Finland
Other retinal vascular occlusions
9.4
21.8
27
31
XCD10
NOMESCO Finland
Electrophysiological examination of eye
8.9
21.7
28
34
CS494
NOMESCO Finland
Other visual field testing
9.6
21.5
26
29
114
Kela drug reimbursment
Glaucoma
4.0
20.8
68
199
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.8
19.1
196
1109
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
2.7
18.9
174
930
H53.4
ICD-10 Finland
Visual field defects
105.8
18.8
20
*
S01ED01
ATC
timolol; ophthalmic
5.9
18.5
35
65
WX140
NOMESCO Finland
Parabulbar anesthesy
5.2
18.3
40
85
CKW99
NOMESCO Finland
Other operation on choroid, vitreous body and retina
44.6
17.5
21
5
AA1AD
NOMESCO Finland
CT of head and brain
2.7
17.3
129
615
H40.5
ICD-10 Finland
Glaucoma secondary to other eye disorders
23.3
17.1
24
11
H43.1
ICD-10 Finland
Vitreous haemorrhage
7.5
16.3
24
34
H26.4
ICD-10 Finland
After-cataract
3.3
14.9
65
228
S01EC01
ATC
acetazolamide; systemic
6.5
14.9
25
41
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.8
13.8
46
135
H57.1
ICD-10 Finland
Ocular pain
5.3
13.8
29
59
H54.4
ICD-10 Finland
Blindness, monocular
+∞
13.6
13
*
H40.13
ICD-10 Finland
Chronic glaucoma with open ventricular angle
3.9
12.8
40
112
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
2.3
12.6
160
946
XCH00
NOMESCO Finland
Eye pressure measurement
4.2
12.3
34
87
H34.1
ICD-10 Finland
Central retinal artery occlusion
39.1
12.3
15
*
H53.2
ICD-10 Finland
Diplopia
22.2
12.1
17
8
S01EE01
ATC
latanoprost; ophthalmic
3.5
12.1
44
137
H53.9
ICD-10 Finland
Visual disturbance, unspecified
11.1
11.9
22
21
H25.1
ICD-10 Finland
Senile nuclear cataract
2.3
11.8
139
791
S01BC05
ATC
ketorolac; ophthalmic
4.2
10.7
29
73
H47.2
ICD-10 Finland
Optic atrophy
61.9
10.7
12
*
H33.0
ICD-10 Finland
Retinal detachment with retinal break
4.8
10.4
24
53
S01EC54
ATC
brinzolamide, combinations; ophthalmic
11.1
10.4
19
18
CS424
NOMESCO Finland
Visual field testing with Goldmann perimetry
24.2
10.3
14
6
TAB00
NOMESCO Finland
Lumbar puncture
4.3
10.2
27
67
CJB10
NOMESCO Finland
Laser discission of secondary cataract
2.9
10.0
51
194
WX100
NOMESCO Finland
Conjunctival surface anesthesia
2.6
10.0
64
275
R51.80
ICD-10 Finland
Headache
2.5
9.7
71
325
S01EE03
ATC
bimatoprost; ophthalmic
5.2
9.7
20
40
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
4.2
9.5
26
66
H04.10
ICD-10 Finland
Dry eye syndrome
2.8
9.5
52
206
H26.02
ICD-10 Finland
Presenil cataract
7.3
9.5
22
32
CKC12
NOMESCO Finland
Photocoagulation of retina
4.3
9.4
25
62
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.0
9.2
175
1167
SPAT1234
SPAT
Support of social functional capacity
3.6
9.1
31
92
H25.8
ICD-10 Finland
Other senile cataract
2.6
8.8
58
252
37300
ICD-8 Finland
Strabismus, Concomitans convergens
28.3
8.5
11
*
H50.1
ICD-10 Finland
Divergent concomitant strabismus
28.3
8.5
11
*
H52.1
ICD-10 Finland
Myopia
4.7
8.2
19
42
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.3
7.9
31
101
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.1
7.8
34
118
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
18.9
7.6
11
6
H3603, E103,
ICD-10 Finland
18.9
7.6
11
6
Z2446
NOMESCO Finland
Social worker
3.0
7.6
35
126
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
7.4
7.6
17
24
H40.10
ICD-10 Finland
Capsular glaucoma with pseudoexfoliation on the anterior lens capsule
4.0
7.4
21
55
Z49.1
ICD-10 Finland
Extracorporeal dialysis
11.2
7.4
13
12
J01DB01
ATC
cefalexin; oral
2.2
7.3
290
2408
H50.31
ICD-10 Finland
Intermittent exotropia
20.5
7.2
10
5
Z94.0
ICD-10 Finland
Kidney transplant status
12.4
7.1
12
10
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.3
7.0
60
293
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.3
7.0
55
259
Z3229
NOMESCO Finland
Other healthcare associate professional
2.5
6.9
44
188
SPAT1149
SPAT
Suture or treatment of traumatic wound
2.4
6.9
53
247
T89
ICPC
Diabetes insulin dependent
3.8
6.9
21
58
CHF05
NOMESCO Finland
Transscleral laser coagulation of ciliary body
17.1
6.8
10
6
H40.0
ICD-10 Finland
Glaucoma suspect
2.7
6.8
37
146
E0000UV, ,
ATC
1.8
6.7
147
1000
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
2.7
6.4
35
138
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.8
6.3
33
127
CK9F4
NOMESCO Finland
Fluorescein angiography (FAG) of choroid and retina
18.4
6.3
9
5
R06.0
ICD-10 Finland
Dyspnoea
1.9
6.3
107
670
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
3.7
6.3
20
57
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
3.5
6.2
21
62
A11CC03
ATC
alfacalcidol; systemic
5.9
6.2
16
28
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
5.9
6.2
16
28
N18.0
ICD-10 Finland
End-stage renal disease
12.8
6.1
10
8
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
2.8
6.1
30
112
CS434
NOMESCO Finland
Visual field testing with Humphrey automated perimetry
5.7
6.1
16
29
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
5.7
6.1
16
29
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
80
329
2.86
13.87
10.5
7.4
—
—
—
0
0
147
838
2.30
12.61
2.2
2.1
133.22
232.73
u/l
2.40
137
783
198
1278
2.27
12.56
9.1
5.5
1.21
1.22
mmol/l
0.17
170
1159
207
1407
2.16
10.97
11.1
6.2
1.22
1.22
mmol/l
0.21
177
1199
198
1340
2.10
10.41
20.0
16.0
1.42
1.33
inr
0.26
28
403
72
328
2.51
9.97
5.7
4.4
36.96
32.47
%
1.82
49
214
117
662
2.15
9.74
2.8
2.2
—
—
—
0
0
230
1678
2.09
9.51
5.8
4.5
6.87
6.75
mmol/l
0.36
219
1547
278
2194
2.31
9.21
9.1
7.1
82.14
79.37
u/l
0.43
253
2047
173
1172
1.94
8.47
2.1
2.0
97.55
93.96
pmol/l
0.39
90
598
51
216
2.59
8.15
13.7
6.5
11.33
9.76
mmol/l
0.75
46
202
100
569
2.06
7.99
1.8
1.7
1088.05
1212.95
nmol/l
0.70
66
434
207
1507
1.92
7.98
5.3
5.9
11.09
11.81
umol/l
0.32
188
1425
39
145
2.90
7.98
1.3
1.3
—
29.57
—
0
9
146
952
1.92
7.86
3.4
3.3
2.36
2.36
mmol/l
0.18
118
839
306
2581
2.51
7.66
6.0
4.6
2.02
1.97
mu/l
0.28
263
2352
163
1115
1.87
7.46
5.2
4.0
89.49
39.46
ng/l
0.55
127
813
41
169
2.62
6.90
1.7
1.9
—
—
—
0
0
173
1227
1.81
6.88
6.5
4.3
35.40
35.22
g/l
0.15
150
1148
328
2903
3.16
6.68
25.8
16.8
4.00
3.97
mmol/l
1.16
318
2816
303
2587
2.30
6.64
4.8
3.9
1.27
1.26
mmol/l
0.10
258
2362
30
107
2.97
6.60
1.8
1.8
—
—
—
0
0
41
174
2.54
6.51
7.3
3.9
1.65
1.83
mmol/l
0.08
34
130
112
705
1.87
6.48
1.5
1.5
19.64
20.95
nmol/l
0.33
87
601
327
2898
3.04
6.48
25.8
16.7
139.41
139.66
mmol/l
1.01
317
2812
312
2706
2.44
6.43
5.3
4.4
4.49
4.59
mmol/l
0.90
278
2499
227
1769
1.81
6.38
3.8
2.9
45.36
46.90
u/l
0.09
197
1656
31
115
2.86
6.37
2.0
2.0
—
—
—
0
0
112
709
1.85
6.35
2.6
2.1
3.41
3.17
mg/l
0.33
90
618
310
2688
2.37
6.28
5.5
4.3
1.48
1.48
mmol/l
0.01
273
2466
317
2776
2.55
6.27
5.8
4.9
2.57
2.69
mmol/l
1.60
282
2548
331
2973
3.20
5.99
13.9
10.2
24.36
25.36
u/l
0.63
308
2858
128
860
1.77
5.88
3.8
3.1
7.07
7.26
mmol/l
0.14
103
716
161
1162
1.72
5.70
2.8
2.2
70.68
77.29
nmol/l
2.43
133
1034
298
2573
2.08
5.63
8.1
5.8
41.82
40.02
mmol/mol
1.80
264
2397
310
2721
2.25
5.53
6.3
4.5
6.10
5.95
mmol/l
1.03
264
2486
254
2093
1.78
5.42
5.6
4.0
12.86
12.95
mm/h
0.03
222
1916
211
1655
1.70
5.35
8.9
9.0
4.43
4.14
e9/l
0.63
182
1467
127
876
1.71
5.20
4.8
2.4
97.89
60.62
u/l
0.48
115
813
62
343
1.98
5.19
11.6
5.3
1.08
1.06
mmol/l
0.21
57
315
15
31
5.01
5.18
1.1
1.1
—
—
—
0
0
128
888
1.70
5.11
4.0
3.3
1844.35
1550.74
ng/l
0.34
108
755
255
2121
1.75
5.07
5.0
3.9
15.02
14.86
pmol/l
0.37
217
1913
80
487
1.83
5.01
1.9
1.9
—
—
—
0
0
316
2824
2.26
4.91
21.5
14.6
23.37
22.99
mg/l
0.06
265
2247
124
862
1.68
4.87
4.6
3.8
14.05
9.49
mg/mmol
0.32
81
539
44
223
2.11
4.66
7.7
3.0
119.46
76.33
ng/l
1.59
37
198
178
1368
1.61
4.63
7.1
5.9
27.15
27.66
%
0.24
159
1301
46
238
2.07
4.62
2.9
2.7
4.65
7.76
ug/l
0.94
35
210
23
87
2.76
4.59
1.2
1.7
—
144.00
—
0
5
176
1353
1.61
4.55
7.0
5.7
58.13
57.19
%
0.48
157
1288
11
19
5.94
4.47
1.4
1.0
—
—
—
0
0
9
12
7.66
4.38
1.1
1.3
—
—
—
0
0
15
45
3.44
4.37
7.7
7.7
127.40
484.30
iu/ml
—
5
10
336
3112
3.14
4.37
31.9
21.4
241.92
247.69
e9/l
0.93
325
3027
336
3115
3.11
4.30
32.0
21.4
39.49
39.74
%
0.28
323
2919
336
3116
3.10
4.28
32.0
21.4
4.40
4.45
e12/l
0.92
322
3020
336
3119
3.07
4.21
32.0
21.5
133.12
133.94
g/l
0.48
329
3062
44
234
2.01
4.10
1.9
2.7
67.02
66.38
g/l
0.21
37
213
296
2630
1.83
4.00
17.3
13.8
76.71
78.88
ml/min/173m2
0.77
242
2140
13
32
4.18
3.94
1.4
1.1
—
—
—
0
0
14
37
3.90
3.94
3.9
3.3
—
885.40
—
0
5
169
1323
1.54
3.81
3.0
2.5
—
—
—
0
0
21
84
2.60
3.79
1.9
1.4
1.48
0.17
iu/ml
—
7
19
11
24
4.70
3.77
5.1
2.4
—
—
—
0
0
155
1198
1.53
3.67
3.5
2.6
139.56
120.97
ug/l
0.50
132
1098
38
201
2.00
3.61
1.3
1.6
—
—
—
0
0
8
13
6.27
3.52
1.1
1.2
—
—
—
0
0
91
629
1.60
3.50
7.5
4.4
1.01
1.02
kg/l
0.74
17
93
12
32
3.85
3.42
1.4
1.1
—
—
—
0
0
6
7
8.69
3.27
1.2
1.4
—
—
—
0
0
10
24
4.26
3.22
1.1
1.1
—
—
—
0
0
8
15
5.43
3.21
1.1
1.1
—
—
—
0
0
46
271
1.80
3.18
5.4
3.8
1.61
2.02
mmol/l
0.31
39
217
47
280
1.78
3.13
1.5
1.6
1.49
1.54
%
0.21
40
248
6
8
7.61
3.06
1.2
1.1
—
—
—
0
0
6
8
7.61
3.06
1.2
1.4
—
—
—
0
0
6
8
7.61
3.06
1.2
1.3
—
—
—
0
0
6
8
7.61
3.06
1.2
1.1
—
—
—
0
0
42
245
1.81
3.00
1.6
1.9
364.42
380.32
nmol/l
0.23
33
226
100
731
1.52
2.96
4.1
2.7
5690.20
9327.60
umol/l
0.27
85
634
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
17
4.79
2.93
1.1
1.2
—
—
—
0
0
7
13
5.47
2.88
2.3
3.2
583.71
828.46
u/ml
—
7
13
176
1444
1.44
2.88
5.7
4.1
0.00
0.00
estimate
-0.00
19
284
136
1065
1.45
2.84
5.6
3.1
—
—
—
0
0
174
1429
1.43
2.80
6.6
5.5
0.00
0.00
estimate
-0.00
18
287
40
236
1.78
2.76
5.3
3.2
4.60
4.30
kpa
0.32
40
226
89
644
1.51
2.75
1.5
1.7
420.75
440.19
pmol/l
0.24
71
536
18
80
2.32
2.65
1.4
1.4
339.01
315.15
ug/g
—
9
42
10
30
3.40
2.62
1.3
1.3
—
—
—
0
0
172
1423
1.41
2.60
5.6
4.1
0.00
0.00
estimate
0.50
20
312
12
44
2.79
2.57
1.3
1.3
—
—
—
0
0
6
11
5.53
2.55
1.0
1.1
80.10
113.74
u/l
—
6
11
6
11
5.53
2.55
1.0
1.1
27.00
44.06
u/l
—
6
11
52
338
1.63
2.54
3.4
4.2
275.13
247.81
u/l
0.23
45
319
31
175
1.85
2.47
1.7
1.4
—
—
—
0
0
24
125
1.99
2.42
1.9
2.3
1.57
1.51
g/l
0.14
19
109
5
8
6.32
2.38
1.2
1.3
—
—
—
0
0
10
33
3.09
2.37
1.3
1.8
—
—
—
0
0
49
320
1.62
2.36
4.5
6.1
0.65
1.32
mmol/l
0.56
35
261
6
13
4.68
2.28
1.0
1.5
—
—
—
0
0
5
9
5.62
2.22
3.2
1.8
—
—
—
0
0
80
593
1.45
2.17
1.8
1.7
1.16
1.28
mg/l
0.18
59
460
25
138
1.87
2.15
1.2
1.0
—
—
—
0
0
12
49
2.50
2.12
1.0
1.3
—
—
—
0
0
5
10
5.05
2.07
2.0
1.3
—
—
—
0
0
40
257
1.63
2.06
4.9
6.8
121.53
121.33
g/l
0.02
40
251
6
15
4.05
2.04
1.7
1.3
3.57
1.84
mmol/l
—
6
15
74
551
1.44
1.95
2.7
3.0
2.44
2.46
mmol/l
0.71
64
479
5
11
4.59
1.95
1.0
1.0
1156.60
1452.18
miu/ml
—
5
11
28
166
1.75
1.94
1.1
1.2
194.43
143.26
iu/ml
0.21
11
73
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
16
78
2.10
1.94
2.5
2.1
0.29
0.34
u/ml
—
10
42
30
182
1.71
1.92
7.0
6.4
24.12
24.33
mmol/l
0.11
30
173
81
616
1.41
1.90
1.4
1.3
0.67
1.59
u/ml
1.63
23
165
18
93
1.99
1.88
1.3
1.2
0.27
3.03
u/ml
—
6
9
99
786
1.36
1.79
6.5
4.4
0.00
0.00
estimate
-0.00
18
281
40
267
1.56
1.78
2.2
2.1
0.21
0.21
g/l
0.17
31
252
134
1115
1.33
1.77
5.9
4.3
—
—
—
0
0
60
439
1.44
1.74
2.6
3.4
0.82
0.81
mmol/l
0.11
53
415
15
75
2.04
1.72
2.9
3.7
1.70
1.56
mg/l
0.25
15
68
8
31
2.62
1.67
1.4
1.8
—
—
—
0
0
6
19
3.19
1.67
1.0
1.7
—
—
—
0
0
48
340
1.48
1.64
1.6
1.9
—
—
—
0
0
5
14
3.61
1.62
1.0
1.1
—
—
—
0
0
47
334
1.47
1.59
2.7
2.5
14.44
9.04
umol/l
0.35
41
282
6
20
3.03
1.58
1.0
1.2
—
—
—
0
0
190
1679
1.29
1.56
3.1
2.9
—
—
—
0
0
47
337
1.46
1.52
1.6
1.9
—
—
—
0
0
7
27
2.62
1.52
1.3
1.3
—
—
—
0
0
10
45
2.26
1.47
1.8
1.4
—
—
—
0
0
15
80
1.91
1.47
1.2
1.9
—
—
—
0
0
0
37
0.00
1.35
0.0
1.1
—
—
—
0
0
14
76
1.88
1.31
2.1
2.5
146.10
57.59
ug/min
—
6
42
8
34
2.38
1.30
1.3
1.6
—
—
—
0
0
8
34
2.38
1.30
1.3
1.6
—
—
—
0
0
12
62
1.97
1.29
1.1
1.1
—
14.88
—
0
6
5
18
2.80
1.29
1.2
1.3
—
—
—
0
0
8
35
2.32
1.27
1.3
1.6
—
—
—
0
0
8
35
2.32
1.27
1.3
1.6
—
—
—
0
0
8
35
2.32
1.27
1.3
1.6
—
—
—
0
0
8
35
2.32
1.27
1.3
1.6
—
—
—
0
0
65
510
1.34
1.26
3.3
2.6
0.96
1.01
e6/l
0.05
43
294
9
45
2.03
1.24
1.3
1.3
153.00
233.44
u/ml
—
9
25
52
396
1.37
1.22
4.1
2.2
21.33
22.34
%
0.19
46
342
31
216
1.48
1.18
2.2
2.5
55.63
64.94
ml/min/173m2
1.42
16
93
5
20
2.52
1.15
1.2
1.2
—
—
—
0
0
12
65
1.88
1.15
2.4
3.3
0.83
0.96
nmol/l
0.35
12
53
7
30
2.36
1.13
2.0
1.1
—
—
—
0
0
5
21
2.40
1.09
3.2
2.1
0.25
0.16
e9/l
—
5
16
105
896
1.25
1.07
3.5
2.7
32.04
33.27
u/l
0.18
99
856
5
22
2.29
1.03
3.2
2.1
391.20
522.00
e6/l
—
5
16
14
84
1.69
0.99
1.6
1.2
—
—
—
0
0
14
86
1.65
0.92
1.6
1.2
—
—
—
0
0
6
28
2.16
0.92
2.0
3.3
19.75
71.95
u/ml
—
6
28
6
29
2.09
0.89
1.0
1.4
—
—
—
0
0
36
275
1.34
0.86
5.8
2.0
27.30
31.82
u/l
0.75
30
231
6
31
1.95
0.85
1.3
1.7
—
—
—
0
0
6
31
1.95
0.85
1.3
1.7
—
—
—
0
0
6
31
1.95
0.85
1.3
1.7
—
—
—
0
0
14
90
1.58
0.79
1.6
1.4
—
—
—
0
0
12
74
1.64
0.79
1.4
1.2
—
—
—
0
0
96
839
1.20
0.77
3.9
3.0
0.21
0.44
e6/l
1.75
76
631
17
117
1.48
0.73
1.8
1.9
4.01
3.44
ug/l
0.06
12
103
5
25
2.01
0.73
1.2
1.2
—
—
—
0
0
5
25
2.01
0.73
1.2
1.2
—
—
—
0
0
9
56
1.62
0.73
2.0
1.4
—
—
—
0
0
9
57
1.59
0.71
1.3
1.6
—
—
—
0
0
9
57
1.59
0.71
1.3
1.6
—
—
—
0
0
5
26
1.94
0.71
1.2
1.2
—
—
—
0
0
5
26
1.94
0.71
1.2
1.2
—
—
—
0
0
5
26
1.94
0.71
1.2
1.2
—
—
—
0
0
23
170
1.38
0.69
6.4
7.3
24.21
24.72
mmol/l
0.37
23
170
10
61
1.66
0.69
1.7
1.4
—
—
—
0
0
9
59
1.54
0.69
1.1
1.4
—
—
—
0
0
7
42
1.68
0.69
1.4
1.1
—
—
—
0
0
5
27
1.86
0.68
2.6
2.8
—
—
—
0
0
5
27
1.86
0.68
1.0
1.4
—
—
—
0
0
8
128
0.62
0.65
4.1
2.9
54.75
1396.00
u/ml
—
8
110
10
63
1.60
0.62
1.2
1.4
—
—
—
0
0
0
21
0.00
0.60
0.0
4.2
—
—
—
0
0
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
0
22
0.00
0.59
0.0
1.5
—
13.18
—
0
22
93
832
1.16
0.57
5.7
4.9
3.02
2.83
ug/l
0.06
83
738
10
65
1.55
0.56
1.1
1.1
—
—
—
0
0
8
126
0.63
0.55
1.4
1.5
—
—
—
0
0
9
60
1.51
0.54
1.4
1.8
—
—
—
0
0
61
530
1.18
0.53
5.4
3.9
38.76
218.56
ng/l
2.06
47
433
6
39
1.55
0.53
1.2
1.3
0.73
0.55
nmol/l
—
6
33
6
39
1.55
0.53
1.0
1.5
—
—
—
0
0
6
39
1.55
0.53
1.0
1.5
—
—
—
0
0
74
655
1.16
0.52
5.4
4.4
22.99
21.71
%
0.25
36
321
12
168
0.70
0.52
1.2
1.2
200.75
193.79
u/ml
0.02
12
158
53
460
1.18
0.48
1.2
1.3
19.49
38.09
iu/ml
1.17
14
159
12
86
1.41
0.45
2.2
2.8
—
—
—
0
0
15
195
0.76
0.43
1.6
1.7
—
—
—
0
0
8
57
1.41
0.42
1.4
1.5
—
—
—
0
0
54
476
1.16
0.41
3.2
3.0
1.16
0.84
ug/l
0.35
31
315
5
33
1.52
0.41
3.6
2.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
2.1
—
80.75
—
0
15
0
17
0.00
0.40
0.0
1.4
—
—
—
0
0
8
61
1.32
0.40
1.4
1.6
39.63
40.48
nmol/l
—
8
61
5
35
1.43
0.39
1.2
1.2
—
—
—
0
0
5
35
1.43
0.39
1.0
1.1
—
2.64
—
0
15
12
89
1.36
0.38
1.2
1.3
—
—
—
0
0
80
737
1.11
0.32
1.6
1.6
1.46
1.33
mmol/l
0.49
69
613
7
52
1.35
0.31
1.0
1.5
—
—
—
0
0
35
306
1.16
0.31
3.6
3.5
—
—
—
0
0
53
479
1.13
0.30
3.5
2.8
1.61
2.28
e6/l
0.70
30
266
20
167
1.21
0.29
1.7
2.7
0.19
0.12
e6/l
0.24
20
160
10
76
1.33
0.28
1.5
1.4
—
—
—
0
0
9
77
1.17
0.24
1.3
1.5
—
—
—
0
0
26
296
0.87
0.24
2.0
2.2
—
—
—
0
0
17
143
1.20
0.23
1.7
1.3
—
—
—
0
0
5
38
1.32
0.23
1.0
1.6
—
—
—
0
0
5
41
1.22
0.22
1.6
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
8.14
—
0
11
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
5
43
1.17
0.21
1.4
1.6
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
309.67
—
0
6
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
14
118
1.19
0.19
3.8
4.8
1.89
1.51
%
0.65
14
110
10
81
1.24
0.19
1.3
1.5
—
—
—
0
0
8
70
1.15
0.16
1.3
1.4
—
—
—
0
0
10
84
1.20
0.14
2.0
1.9
—
—
—
0
0
14
122
1.15
0.14
1.8
1.9
—
—
—
0
0
5
45
1.11
0.10
1.0
1.5
—
—
—
0
0
14
152
0.92
0.06
4.7
3.0
36.36
52.74
u/ml
0.26
14
145
16
150
1.07
0.04
1.9
2.0
—
—
—
0
0
10
91
1.10
0.04
1.3
2.0
—
—
—
0
0
12
111
1.08
0.04
1.3
2.1
—
—
—
0
0
25
260
0.96
0.03
1.8
2.0
—
—
—
0
0
45
459
0.98
0.02
1.6
1.4
—
—
—
0
0
42
414
1.02
0.00
1.6
1.4
—
—
—
0
0
44
441
1.00
0.00
1.3
1.3
1.44
8.71
u/ml
2.69
12
169
5
55
0.91
0.00
1.2
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
6
63
0.95
-0.00
1.3
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
22.82
—
0
5
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
63
0.95
-0.00
1.3
1.4
—
—
—
0
0
7
70
1.00
-0.00
1.3
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
7.30
—
0
9
0
9
0.00
-0.00
0.0
8.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
7.31
—
0
7
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_SEVVISIMPMONOC and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_SEVVISIMPMONOC | 1.039 [0.83, 1.3] | 0.732 |
| Birth year | 0.998 [0.99, 1.01] | 0.58 |
During the follow-up period (1.1.1998 — 31.12.2019), 187 out of 1136 females with H7_SEVVISIMPMONOC died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_SEVVISIMPMONOC | 1.545 [1.1, 2.16] | 0.011 |
| Birth year | 0.987 [0.98, 1.0] | 0.005 |
During the follow-up period (1.1.1998 — 31.12.2019), 158 out of 954 males with H7_SEVVISIMPMONOC died.
Mortality risk
Mortality risk for people of age
years, who have H7_SEVVISIMPMONOC.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.117% | 0.283% |
| 5 | 0.654% | 1.82% |
| 10 | 1.606% | 4.232% |
| 15 | 3.138% | 8.11% |
| 20 | 5.713% | 14.077% |
Relationships between endpoints
↥Index endpoint: H7_SEVVISIMPMONOC – Severe visual impairment, monocular
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data